Boston Scientific has been awarded FDA approval for their newest drug eluting stent, the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System. Despite the thin strut design, the stent is touted by the company as having excellent structural properties. According to Boston Scientific, when compared with certain cobalt alloy stents the Promus PREMIER has as much as 136% greater radial strength and 140% higher axial strength, yet is still up to 900% more conformable. The additional flexibility along with a Bi-Segment inner lumen catheter, dual layer PEBAX balloon, shorter red tip, and fluorinated co-polymer should help physicians navigate through tortuous vessels and improve visibility and deliverability. Clinical trial results were very positive, with 0% target lesion revascularization and stent thrombosis, and a 99.2% technical success rate.
Promus PREMIER was awarded CE Mark approval in February this year, and is currently available in 94 sizes to accommodate unique and challenging diseased vasculature.